Advances in metabolomics of cholangiocarcinoma
10.12206/j.issn.2097-2024.202211025
- VernacularTitle:胆管癌代谢组学研究进展
- Author:
Yongping HE
1
;
Yang JIAO
2
;
Yue LIU
3
Author Information
1. Department of Pharmaceutical Analysis, School of Pharmacy, Naval Medical University, Shanghai 200433, China;School of Pharmacy, Guangxi Medical University, Nanning 530021, China;Department of Pharmacy, the People's Hospital of Chongzuo, Chongzuo 532200, China.
2. School of Pharmacy, Guangxi Medical University, Nanning 530021, China.
3. Department of Pharmaceutical Analysis, School of Pharmacy, Naval Medical University, Shanghai 200433, China;Shanghai Key Laboratory for Pharmaceutical Metabolite Research, Shanghai 200433, China.
- Keywords:
cholangiocarcinoma;
metabolomic;
biomarkers;
mechanism;
early diagnosis;
pharmacodynamic evaluation
- From:
Journal of Pharmaceutical Practice
2023;41(12):705-709
- CountryChina
- Language:Chinese
-
Abstract:
As a highly malignant tumor, the diagnosis of cholangiocarcinoma (CCA) is often late and the prognosis is poor for which the early symptoms are atypical and the lack of accurate biomarkers. Metabolomics is an emerging science that researches the alterations of all endogenous small molecule metabolites in an organism under the influence of pathological, physiological or genetic modification. The development and progress of CCA is closely related to metabolism. Metabolomic is characterized by global analysis, high throughput and reflects real-time alterations in biology system, providing a new avenue for biomarker screening and diseases diagnosis and treatment. The advances of metabolomics studies on CCA in the recent years were reviewed in this paper which could provide the reference for further research.
